Immuneering (IMRX) investor relations material

Executive summary

• Focused on developing Deep Cyclic Inhibitors for oncology, with atebimetinib (IMM-1-104) as the lead candidate in Phase 3 trials for pancreatic cancer and ongoing Phase 1/2a trials for advanced solid tumors.

• Announced positive interim data for atebimetinib in combination with mGnP in first-line pancreatic cancer and expects further data in Q2 2026.

• New survival data from a Phase 2a trial of atebimetinib + mGnP in first-line metastatic pancreatic cancer to be presented at the 2026 ASCO Annual Meeting.

• Pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line metastatic pancreatic cancer is now recruiting, with first patient dosing expected by mid-2026.

• 27 months progression-free survival observed in a third-line pancreatic cancer patient on atebimetinib monotherapy, with an 85% reduction in tumor burden.

Financial highlights

• Net loss for Q1 2026 was $13.5 million, a 10.5% improvement from $15.0 million in Q1 2025.

• Research and development expenses decreased 7.2% year-over-year to $10.6 million, mainly due to prioritization of atebimetinib and reduced spend on envometinib.

• General and administrative expenses increased 16.9% year-over-year to $4.7 million, driven by higher employee and professional costs.

• Cash, cash equivalents, and marketable securities totaled $198.6 million as of March 31, 2026, down from $217.0 million at December 31, 2025.

• Interest income for Q1 2026 was $1.36 million, up from $0.44 million in Q1 2025.

Outlook and guidance

• Existing cash and investments expected to fund operations into 2029, based on current plans.

• First patient dosing in the MAPKeeper 301 Phase 3 trial for atebimetinib in pancreatic cancer anticipated mid-2026.

• Additional clinical milestones expected in 2026, including expanded survival and safety data and initiation of a lung cancer trial.